今年以来，创新药成为公募基金收益来源的关键 "胜负手"。 港股创新药表现尤为突出。据 Choice数据统计，截至7月21日，国证港股通创新药指数（987018.SZ） （在港股通范围内选择业务涉及创新药研发生产的 50只代表性股票，主要聚焦其他生物制品、化学制剂两大领域） 暴涨 93.94%。 部分 "先手"玩家，一扫过去4年的低迷，包揽业绩排行榜的金字塔尖。 据 Choice数据统计，截至7月21日，年内已有6只基金收益翻倍（涨超100%），均为 重仓 创新药 的主动权益 基金。 此外，在 30只年内收益超80%的基金中，29只为配置创新药行业的主动或被动产品。 | 证券代码 | 证券名称 | 东财基金三级分类 | 量经经理 | 任职日期 | 今年以来回报 | 2024年回报 | 近3年回报 | 近5年回报 | 高会规模 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | [单位]% | [章位]% | [单位]% | [单位]% | [单位]亿元 | | 470888.OF | 汇添富香港优势精选混合(QD ...

□本报记者 王鹤静 上周（7月14日至7月18日），创新药、AI算力等板块走强，相关主题ETF水涨船高，华泰柏瑞恒生创新 药ETF等5只港股创新药主题ETF涨超13%，多只人工智能以及通信、云计算等主题ETF涨超10%。与此 同时，游戏、地产、金融科技等主题ETF表现相对平淡。 7月17日首批10只科创债ETF上市以来，两个交易日大举"吸金"，10只ETF合计净流入近600亿元，总规 模由最初不足290亿元大幅增至880亿元以上。此外，证券、红利低波以及半导体主题ETF也迎来了增量 配置资金。 港股创新药ETF水涨船高 易方达中证香港证券投资主题ETF上周净流入超24亿元，位居股票型ETF首位。嘉实上证科创板芯片 ETF、国泰中证全指证券公司ETF、南方标普中国A股大盘红利低波50ETF、华泰柏瑞红利低波动ETF、 国联安中证全指半导体ETF净流入额均在14亿元以上，居市场前列。 龙头宽基ETF的资金流出迹象较为明显，跟踪中证A500、沪深300、创业板指的ETF上周合计净流出近 200亿元。华泰柏瑞沪深300ETF、易方达创业板ETF分别净流出32.52亿元、22.69亿元。7月以来，跟踪 中证A500指数 ...

以下文章来源于财经图解 ，作者十字路口 财经图解 . 财经大事早知道，关注东方财富股票！ 周四（7月17日）创新药概念大爆发，神州细胞涨超15%，康诺亚大涨超14%，康方生物、百奥泰涨超 10%，先声药业、益方生物、众生药业、康龙化成、恒瑞医药、华东医药等跟涨。 消息面上，据光明网，第十一批国家组织药品集中采购工作近日启动，国家医保局价格招采司负责人表 示，坚持集采非新药、新药不集采，科学确定采购品种。为保护行业创新积极性，与医保目录谈判相衔 接，排除了通过谈判新进入医保且仍在协议期内的品种。 文章转载自公众号"财经图解"，以上观点来自相关机构，不代表天天基金的观点，不对观点 的准确性和完整性做任何保证。收益率数据仅供参考，过往业绩和走势风格不预示未来表 现，不构成投资建议。转引的相关观点均来自相关机构或公开媒体渠道，不代表天天基金的 ↓ 点击"阅读原文" 或上天天基金APP搜索【777】 注册领500元券包 ，优选基金10元起投！ 《措施》为支持创新药发展提供双重保障。一方面，医保目录将动态调整，符合条件的创新药按程序纳 入，重大公共卫生事件急需药品甚至可探索临时纳入路径。医保支付标准的制定将更科学合理，运 ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

今日，港股三大指数整体呈现窄幅震荡行情，尾盘短线跳水。 影视股表现活跃，比高集团涨超10%，大麦娱乐涨超8%，丰德丽控股、IMAX中国涨超2%，猫眼娱乐、 欢喜传媒涨超1%。 恒生指数、国企指数分别微幅下跌0.08%、0.09%，恒生科技指数表现相对较强，最终收涨0.56%。 | 代码 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | --- | | 800000 | 恒生指数 | (0) | 24498.95 | -18.81 | -0.08% | | CONSULT DOGES BY 800100 | 国企指数 | | 8853.10 | -8.29 | -0.09% | | 800700 | 恒生科技指数 | | 5448.85 | +30.45 | 0.56% | 盘面上，大型科技股涨跌不一，美团涨超1%，网易、腾讯飘红，百度跌超3%，小米跌2%，阿里巴巴跌 超1%。 生物医药股大肆走高，创新药午后涨幅进一步扩大，康诺亚大涨14.5%，康方生物、百济神州涨超10%， 泰格医药、金斯瑞生物科技、科伦博泰生物涨超8%。 半导体芯片股、军工 ...

从消息面来看，近期，创新药板块的利好消息不断。接下来，这个板块的行情是否会持续下去呢？ 创新药概念股集体爆发 自6月底以来，创新药板块一路上行，最近几天更是加速上涨。7月17日，创新药板块指数涨幅超过3%，成都 先导、迈威生物、维康药业、塞力医疗、力生制药、亚太药业、信立泰等近20只相关概念股涨停或涨超10%。 7月17日，创新药领域又传来一则好消息。据北京日报报道，近日，我国自主研发的、抗呼吸道合胞病毒的创 新药——齐瑞索韦列入世界卫生组织儿童药物优化优先清单，有望为全球儿童带来可及、可负担的有效治疗。 据报道，世界卫生组织儿童药物优化（PADO）项目通过凝聚监管机构、资助方与制造商共识，推动有紧迫需 求的儿童药物加速开发，工作内容包括确定研发的重点优先产品及其理想的产品特性。 创新药板块，再次掀起涨停潮！ 今日（7月17日），A股三大指数集体拉升，截至收盘，沪指涨0.37%，深证成指涨1.43%，创业板指涨1.76%。 盘面上，创新药、CPO、AI硬件等方向领涨。其中，创新药概念股集体大涨，成都先导、塞力医疗、力生制药 等近20只相关概念股涨停或涨超10%。 在港股市场上，创新药概念股也集体爆发，截至收盘 ...

智通财经7月17日电，截至发稿，三叶草生物(02197.HK)涨28.17%、复旦张江(01349.HK)涨22.86%、康 诺亚-B(02162.HK)涨11.10%、康方生物(09926.HK)涨11.03%。 港股医药股延续涨势 三叶草生物涨超28% ...

Group 1 - The innovative drug sector is experiencing a strong rally, with significant stock price increases for companies such as Lepu Biopharma-B (up 11.15%), CanSino Biologics (up 9.92%), and others [1] - Recent favorable news for the innovative drug industry includes the initiation of the 11th batch of national drug centralized procurement, which will not include innovative drugs, focusing instead on mature "old drugs" [1] - The National Healthcare Security Administration and the National Health Commission have issued measures to support the high-quality development of innovative drugs, including 16 specific initiatives across R&D support, medical insurance access, and clinical application [1] Group 2 - According to Zhongyou Securities, the innovative drug sector is expected to continue its positive trend due to overseas large-scale business development (BD) expectations and supportive policy documents [2] - The core driving force behind the current Hong Kong stock market's innovative drug rally is value reassessment, with current valuations still considered attractive [2] - Domestic capital has been increasing its positions through the Hong Kong Stock Connect, while foreign capital remains at a low position in innovative drugs, indicating a preference for fundamentally solid and cost-effective stocks [2]

Core Insights - The pharmaceutical-themed funds are dominating the performance rankings for the first half of the year, with nine out of the top ten funds being pharmaceutical-focused, led by Huatai-PineBridge Hong Kong Advantage Select A, which achieved a 103.67% return [1][2] - The strong performance of these funds is driven by multiple factors, including breakthroughs in innovative drug development, recovery of liquidity in the Hong Kong stock market, and restructuring of valuation systems through cross-border business development transactions [1][2] Fund Performance - The average return of the top ten actively managed equity funds exceeds 69%, with notable performances from Changcheng Pharmaceutical Industry Select A and Yongying Pharmaceutical Innovation Smart Select A, achieving returns of 87.73% and 79.79% respectively [2] - Huatai-PineBridge Hong Kong Advantage Select A is highlighted as a "doubling fund" for the year, marking a significant achievement in the market [2] Market Dynamics - The pharmaceutical sector is experiencing a "double hit" in profitability and valuation in 2025, with the Hang Seng Hong Kong Stock Connect Innovative Drug Index showing a year-to-date increase of 70.09% [3] - The performance of pharmaceutical funds is significantly influenced by their exposure to Hong Kong stocks, with the Hang Seng Healthcare Index rising by 54.59%, outperforming the A-share innovative drug index, which increased by 24.15% [3] Investment Strategy - Huatai-PineBridge Hong Kong Advantage Select A has benefited from investments in leading companies in the Hong Kong innovative drug and medical device sectors, capitalizing on improved overseas liquidity and favorable industry policies [4] - The introduction of financing channels for unprofitable biotech companies in Hong Kong has allowed competitive biotech firms to enter the market, with many now in advanced stages of research and commercialization [4] Future Outlook - The pharmaceutical industry is expected to maintain long-term investment value driven by demographic aging, consumption upgrades, and technological innovation, although caution is advised regarding potential overvaluation of certain stocks [6] - The current market for innovative drugs is characterized by high valuations and volatility, with expectations for a rebalancing between these factors in the near future [6][7] - The valuation of leading companies and key stocks is anticipated to be reassessed, with a focus on the long-term potential of authorized products and revenue realization from commercial partnerships [7]

Company Overview - 康诺亚生物医药科技有限公司 (康诺亚-B) focuses on innovation and research, aiming to provide high-quality and affordable therapies for patients, positioning itself as a "Noah's Ark" for health [2] - The company has a strong leadership team composed of top experts in the biopharmaceutical industry, with extensive experience in technology transfer and industrialization [2] - 康诺亚 has developed a comprehensive biopharmaceutical value chain, covering molecular discovery, process development, translational medicine, clinical development, and commercial production [2] Financial Performance - As of December 31, 2024, 康诺亚-B reported total revenue of 428 million yuan, a year-on-year increase of 20.91% [1] - The company recorded a net loss attributable to shareholders of 515 million yuan, a decrease of 43.38% compared to the previous year [1] - The gross profit margin stood at 97.15%, with a debt-to-asset ratio of 34.28% [1] Market Position and Valuation - 康诺亚-B's price-to-earnings (P/E) ratio is -23.6, ranking 103rd in the industry, while the average P/E ratio for the pharmaceutical and biotechnology sector is 4.2 [1] - The company has a competitive product pipeline in the fields of autoimmune diseases and oncology, with over 30 innovative drugs under development, including 9 in various stages of clinical research [2] - 康诺亚's clinical supply base meets the standards of NMPA, FDA, and EMA, ensuring the safety of clinical supplies [2] Future Developments - A new antibody drug production base is under construction in Chengdu, which will have a fermentation capacity of 80,000 liters, capable of supporting the commercial production of 5-15 antibodies [2] - The company is rapidly growing into a comprehensive biopharmaceutical firm, committed to providing reliable and affordable innovative biological drugs to patients [2]